Get to know our clinical trials

Phase III study of ribociclib in patients with advanced breast cancer

THE OBJECTIVE OF THE RESEARCH STUDY IS TO DETERMINE WHETHER PATIENTS WITH THE SPECIFIC HER2-ENRICHED SUBTYPE WILL HAVE LONGER TIME TO DISEASE PROGRESSION IF TREATED WITH RIBOCICLIB INSTEAD OF PALBOCICLIB.

Imagen del Dr. Jaime Espinós Jiménez, especialista en Oncología Médica de la Clínica Universidad de Navarra.
Dr. Jaime Espinós Curriculum
Specialist Medical Oncology Department
Madrid headquarters
Cancer Center
Breast Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE III, MULTICENTER, OPEN-LABEL STUDY OF RIBOCICLIB COMPARED TO PALBOCICLIB IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE/HER2-ENRICHED ADVANCED BREAST CANCER PATIENTS - HARMONIA TRIAL.
  • Code EudraCT: 2021-002027-38
  • Protocol number: SOLTI-2101
  • Promoter: SOLTI (Grupo Español De Estudio, Tratamiento Y Otras Estrategias Experimentales En Tumores Sólidos)
  • Molecule/Drug: ribociclib

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION